Ergomed (ERGO)

 

Latest News

Board and Management Changes

RNS Number: 3757C Ergomed plc 13 April 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Board and Management Changes London, UK - 13 April 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces Board and...

Director Deals - Ergomed Plc (ERGO)

Peter George, Non Executive Director, bought 100,000 shares in the company on the 3rd April 2017 at a price of 190.00p. The...

Director/PDMR Shareholding

RNS Number: 5275B Ergomed plc 04 April 2017 Ergomed Plc ("Ergomed" or the "Company") Director Dealing Ergomed, a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that on 3 April 2017, Mr Peter George, Chairman of the Company, bought 100,000 ordina...

Ergomed partner announces successful data

Ergomed has noted that co-development partner, Asarina Pharma, has today announced the publication of its phase IIa cli...

All News

DateHeadlineSource
13-04-17Board and Management ChangesRNS
04-04-17Director Deals - Ergomed Plc (ERGO)StockMarketWire
04-04-17Director/PDMR ShareholdingRNS
03-04-17Ergomed partner announces successful dataStockMarketWire
03-04-17Partner Asarina Pharma announces successful dataRNS
28-03-17Ergomed revenues up 30%StockMarketWire
28-03-17Ergomed revenues up StockMarketWire
28-03-17Unaudited Preliminary Results for 2016RNS
21-03-17Notice of Preliminary ResultsRNS
20-03-17Ergomed initiates study of PeprostatStockMarketWire
20-03-17Initiates Phase II Study of Topical PeproStatRNS
20-02-17Ergomed notes partner's successful financing roundStockMarketWire
20-02-17Modus Therapeutics Raises SEK 32 MillionRNS
06-02-17Broker Forecast - Numis issues a broker note on Ergomed PlcStockMarketWire
06-02-17Broker Forecast - Stifel issues a broker note on Ergomed PlcStockMarketWire
06-02-17Positive Phase II top-line results of LorediplonRNS
03-02-17Broker Forecast - N+1 Singer issues a broker note on Ergomed PlcStockMarketWire
31-01-17Completion of ZoptrexT Phase 3 Clinical TrialRNS
17-01-1725 momentum stocks for 2017Interactive Investor
17-01-17Ergomed revenues up 26%StockMarketWire
17-01-17Trading StatementRNS
01-12-16Ergomed CFO and general counsel granted optionsStockMarketWire
30-11-16Award of Options by CEO to CFO and General CounselRNS
29-11-16Acquisition of PharmInventRNS
21-11-16Ergomed chairman to step down StockMarketWire
21-11-16Proposed Board ChangesRNS
16-11-16Ergomed expands clinical study with Modus TherapeuticsStockMarketWire
16-11-16Research Update from Modus TherapeuticsRNS
15-11-16Holding(s) in CompanyRNS
07-11-16Broker Forecast - N+1 Singer issues a broker note on Ergomed PlcStockMarketWire
01-11-16Co-Development Agreement with Asarina ABRNS
24-10-16Ergomed notes Dilaforette's plans for IPO StockMarketWire
24-10-16Ergomed notes news from co-development partnerRNS
21-10-16Broker Forecast - N+1 Singer issues a broker note on Ergomed PlcStockMarketWire
14-10-16Fourth licensing agreement for ZoptrexRNS
26-09-16Ergomed revenues up StockMarketWire
26-09-16Half-year ReportRNS
22-09-16Ergomed contract win StockMarketWire
22-09-16Contract win validates rationale of acquisitionsRNS
16-09-16Ergomed receives a "buy" recommendationRNS

RSS feeds

  • Editorial news feed for LSE:ERGO Editorial
  • Regulatory news feed for LSE:ERGO Regulatory